Atezolizumab in patients with advanced non-small-cell lung cancer who are platinum-doublet ineligible
- PMID: 37423230
- DOI: 10.1016/S0140-6736(23)00807-3
Atezolizumab in patients with advanced non-small-cell lung cancer who are platinum-doublet ineligible
Conflict of interest statement
HO'S has received honorarium from Amgen and expenses from Takeda, all outside the scope of the submitted work. SP has received honoraria from Amgen, AstraZeneca, Bayer, Blueprint, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, EQRx, GlaxoSmithKline, Guardant Health, Incyte, Janssen, Lilly, Merck Serono, Merck, Novartis, Roche, Takeda, Pfizer, Seattle Genetics, and Turning Point Therapeutics; honoraria for educational lectures from AstraZeneca, Bayer, Guardant Health, Janssen, Merck Serono, Roche, and Takeda; and provided expert testimony for Roche and Merck Serono, all in the field of precision medicine and lung cancer drug development.
Comment on
-
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.Lancet. 2023 Aug 5;402(10400):451-463. doi: 10.1016/S0140-6736(23)00774-2. Epub 2023 Jul 6. Lancet. 2023. PMID: 37423228 Clinical Trial.
Similar articles
-
Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy.J Oncol Pharm Pract. 2020 Apr;26(3):564-571. doi: 10.1177/1078155219855127. Epub 2019 Jun 25. J Oncol Pharm Pract. 2020. PMID: 31238808
-
Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC).Anticancer Res. 2013 Aug;33(8):3275-8. Anticancer Res. 2013. PMID: 23898091
-
Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?Cancer. 2018 Dec 15;124(24):4592-4596. doi: 10.1002/cncr.31681. Epub 2018 Nov 1. Cancer. 2018. PMID: 30383887 Free PMC article. No abstract available.
-
Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.Cancer Treat Rev. 2020 Apr;85:101979. doi: 10.1016/j.ctrv.2020.101979. Epub 2020 Feb 4. Cancer Treat Rev. 2020. PMID: 32078962 Review.
-
Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis.Front Immunol. 2021 Jun 2;12:666909. doi: 10.3389/fimmu.2021.666909. eCollection 2021. Front Immunol. 2021. PMID: 34149702 Free PMC article.
Cited by
-
Atezolizumab monotherapy as first-line treatment for non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a cost-effectiveness analysis in the USA.BMJ Open. 2024 Nov 12;14(11):e083716. doi: 10.1136/bmjopen-2023-083716. BMJ Open. 2024. PMID: 39532375 Free PMC article.
-
Toxicity of Cancer Immunotherapies in Older Patients: Does Age Make a Difference?Drugs Aging. 2024 Oct;41(10):787-794. doi: 10.1007/s40266-024-01149-2. Epub 2024 Oct 5. Drugs Aging. 2024. PMID: 39368044 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical